THE UNIVERSITY OF MANCHESTER

Sonrai and Paige Partner to Accelerate Precision Medicine R&D with Advanced AI Capabilities

a month ago

• Sonrai Analytics and Paige have formed a strategic partnership to integrate Paige's foundation models with Sonrai's cloud-based bioinformatics platform, making advanced AI capabilities accessible to non-technical users in biopharma. • The collaboration aims to accelerate drug discovery, biomarker identification, and precision medicine applications by enabling researchers to extract deeper insights from multi-modal data including multi-omics and imaging. • The partnership represents a significant advancement in AI-powered pharmaceutical research, particularly for developing AI-driven biomarkers in cancer and other diseases without requiring deep AI expertise.

Sulthiame Shows Promise in Treating Obstructive Sleep Apnea, Leads ERS Congress 2024 Highlights

6 months ago

• A clinical trial presented at ERS Congress 2024 revealed that sulthiame, an epilepsy medication, effectively reduced obstructive sleep apnea symptoms by improving oxygen levels and decreasing breathing interruptions during sleep. • Researchers at ERS Congress discussed critical findings on lung function decline in IPF and PPF patients, demonstrating that even minor decreases in lung function significantly impact mortality risk and transplant likelihood. • The congress highlighted emerging trends in respiratory medicine, including AI-powered robotics potential in clinical care and key lessons from failed IPF trials emphasizing the need for improved trial design.

UK to Trial Eli Lilly's Mounjaro for Obesity to Boost Employment

7 months ago

• The UK will conduct a major real-world study on Eli Lilly's tirzepatide (Mounjaro) to assess its effectiveness in helping obese individuals return to work. • The University of Manchester will coordinate the study, involving up to 3,000 participants, to evaluate the drug's impact on health-related quality of life and employment status. • NHS plans to provide Mounjaro to nearly a quarter of a million people over three years, aiming to reduce obesity-related burdens on the healthcare system. • Health officials emphasize that lifestyle changes are crucial alongside drug treatment to ensure the sustainability of health improvements and reduce strain on the NHS.